TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Homo sapiens (Human))
Shengke Pharmaceuticals (Jiangsu)
US Patent
Shengke Pharmaceuticals (Jiangsu)
US Patent
Affinity DataIC50: 6.18nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Homo sapiens (Human))
Changzhou Longthera Pharmaceuticals
US Patent
Changzhou Longthera Pharmaceuticals
US Patent
Affinity DataIC50: <10nMAssay Description:The test compound was dissolved in dimethyl sulfoxide and the solution was diluted to each concentration gradient with a buffer (50 mM HEPES, 10 mM M...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Homo sapiens (Human))
Changzhou Longthera Pharmaceuticals
US Patent
Changzhou Longthera Pharmaceuticals
US Patent
Affinity DataIC50: <10nMAssay Description:The test compound was dissolved in dimethyl sulfoxide and the solution was diluted to each concentration gradient with a buffer (50 mM HEPES, 10 mM M...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Homo sapiens (Human))
Changzhou Longthera Pharmaceuticals
US Patent
Changzhou Longthera Pharmaceuticals
US Patent
Affinity DataIC50: <10nMAssay Description:The test compound was dissolved in dimethyl sulfoxide and the solution was diluted to each concentration gradient with a buffer (50 mM HEPES, 10 mM M...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Homo sapiens (Human))
Changzhou Longthera Pharmaceuticals
US Patent
Changzhou Longthera Pharmaceuticals
US Patent
Affinity DataIC50: <10nMAssay Description:The test compound was dissolved in dimethyl sulfoxide and the solution was diluted to each concentration gradient with a buffer (50 mM HEPES, 10 mM M...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Homo sapiens (Human))
Changzhou Longthera Pharmaceuticals
US Patent
Changzhou Longthera Pharmaceuticals
US Patent
Affinity DataIC50: <10nMAssay Description:The test compound was dissolved in dimethyl sulfoxide and the solution was diluted to each concentration gradient with a buffer (50 mM HEPES, 10 mM M...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Homo sapiens (Human))
Changzhou Longthera Pharmaceuticals
US Patent
Changzhou Longthera Pharmaceuticals
US Patent
Affinity DataIC50: <10nMAssay Description:The test compound was dissolved in dimethyl sulfoxide and the solution was diluted to each concentration gradient with a buffer (50 mM HEPES, 10 mM M...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Homo sapiens (Human))
Changzhou Longthera Pharmaceuticals
US Patent
Changzhou Longthera Pharmaceuticals
US Patent
Affinity DataIC50: <10nMAssay Description:The test compound was dissolved in dimethyl sulfoxide and the solution was diluted to each concentration gradient with a buffer (50 mM HEPES, 10 mM M...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Homo sapiens (Human))
Changzhou Longthera Pharmaceuticals
US Patent
Changzhou Longthera Pharmaceuticals
US Patent
Affinity DataIC50: <10nMAssay Description:The test compound was dissolved in dimethyl sulfoxide and the solution was diluted to each concentration gradient with a buffer (50 mM HEPES, 10 mM M...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Homo sapiens (Human))
Changzhou Longthera Pharmaceuticals
US Patent
Changzhou Longthera Pharmaceuticals
US Patent
Affinity DataIC50: <10nMAssay Description:The test compound was dissolved in dimethyl sulfoxide and the solution was diluted to each concentration gradient with a buffer (50 mM HEPES, 10 mM M...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Homo sapiens (Human))
Changzhou Longthera Pharmaceuticals
US Patent
Changzhou Longthera Pharmaceuticals
US Patent
Affinity DataIC50: <10nMAssay Description:The test compound was dissolved in dimethyl sulfoxide and the solution was diluted to each concentration gradient with a buffer (50 mM HEPES, 10 mM M...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Homo sapiens (Human))
Changzhou Longthera Pharmaceuticals
US Patent
Changzhou Longthera Pharmaceuticals
US Patent
Affinity DataIC50: <10nMAssay Description:The test compound was dissolved in dimethyl sulfoxide and the solution was diluted to each concentration gradient with a buffer (50 mM HEPES, 10 mM M...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Homo sapiens (Human))
Changzhou Longthera Pharmaceuticals
US Patent
Changzhou Longthera Pharmaceuticals
US Patent
Affinity DataIC50: <10nMAssay Description:The test compound was dissolved in dimethyl sulfoxide and the solution was diluted to each concentration gradient with a buffer (50 mM HEPES, 10 mM M...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Homo sapiens (Human))
Changzhou Longthera Pharmaceuticals
US Patent
Changzhou Longthera Pharmaceuticals
US Patent
Affinity DataIC50: <10nMAssay Description:The test compound was dissolved in dimethyl sulfoxide and the solution was diluted to each concentration gradient with a buffer (50 mM HEPES, 10 mM M...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Homo sapiens (Human))
Changzhou Longthera Pharmaceuticals
US Patent
Changzhou Longthera Pharmaceuticals
US Patent
Affinity DataIC50: <10nMAssay Description:The test compound was dissolved in dimethyl sulfoxide and the solution was diluted to each concentration gradient with a buffer (50 mM HEPES, 10 mM M...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Homo sapiens (Human))
Changzhou Longthera Pharmaceuticals
US Patent
Changzhou Longthera Pharmaceuticals
US Patent
Affinity DataIC50: <10nMAssay Description:The test compound was dissolved in dimethyl sulfoxide and the solution was diluted to each concentration gradient with a buffer (50 mM HEPES, 10 mM M...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Homo sapiens (Human))
Changzhou Longthera Pharmaceuticals
US Patent
Changzhou Longthera Pharmaceuticals
US Patent
Affinity DataIC50: <10nMAssay Description:The test compound was dissolved in dimethyl sulfoxide and the solution was diluted to each concentration gradient with a buffer (50 mM HEPES, 10 mM M...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Homo sapiens (Human))
Shengke Pharmaceuticals (Jiangsu)
US Patent
Shengke Pharmaceuticals (Jiangsu)
US Patent
Affinity DataIC50: 22.5nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Homo sapiens (Human))
Shengke Pharmaceuticals (Jiangsu)
US Patent
Shengke Pharmaceuticals (Jiangsu)
US Patent
Affinity DataIC50: 23.9nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Homo sapiens (Human))
Shengke Pharmaceuticals (Jiangsu)
US Patent
Shengke Pharmaceuticals (Jiangsu)
US Patent
Affinity DataIC50: 30.9nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Homo sapiens (Human))
Changzhou Longthera Pharmaceuticals
US Patent
Changzhou Longthera Pharmaceuticals
US Patent
Affinity DataIC50: 55nMAssay Description:The test compound was dissolved in dimethyl sulfoxide and the solution was diluted to each concentration gradient with a buffer (50 mM HEPES, 10 mM M...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Homo sapiens (Human))
Changzhou Longthera Pharmaceuticals
US Patent
Changzhou Longthera Pharmaceuticals
US Patent
Affinity DataIC50: 55nMAssay Description:The test compound was dissolved in dimethyl sulfoxide and the solution was diluted to each concentration gradient with a buffer (50 mM HEPES, 10 mM M...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Homo sapiens (Human))
Shengke Pharmaceuticals (Jiangsu)
US Patent
Shengke Pharmaceuticals (Jiangsu)
US Patent
Affinity DataIC50: 61.8nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Homo sapiens (Human))
Shengke Pharmaceuticals (Jiangsu)
US Patent
Shengke Pharmaceuticals (Jiangsu)
US Patent
Affinity DataIC50: 67nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Homo sapiens (Human))
Shengke Pharmaceuticals (Jiangsu)
US Patent
Shengke Pharmaceuticals (Jiangsu)
US Patent
Affinity DataIC50: 104nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Mus musculus (mouse))
Johnson & Johnson Pharmaceutical
Johnson & Johnson Pharmaceutical
Affinity DataIC50: 110nMAssay Description:The enzyme was assayed with a biotinylated peptide substrate and test compounds in the presence of 10 uM ATP/[gamma-33P]ATP in a streptavidin coated...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Homo sapiens (Human))
Shengke Pharmaceuticals (Jiangsu)
US Patent
Shengke Pharmaceuticals (Jiangsu)
US Patent
Affinity DataIC50: 116nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Mus musculus (mouse))
Johnson & Johnson Pharmaceutical
Johnson & Johnson Pharmaceutical
Affinity DataIC50: 120nMAssay Description:The enzyme was assayed with a biotinylated peptide substrate and test compounds in the presence of 10 uM ATP/[gamma-33P]ATP in a streptavidin coated...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Homo sapiens (Human))
Shengke Pharmaceuticals (Jiangsu)
US Patent
Shengke Pharmaceuticals (Jiangsu)
US Patent
Affinity DataIC50: 123nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Homo sapiens (Human))
Shengke Pharmaceuticals (Jiangsu)
US Patent
Shengke Pharmaceuticals (Jiangsu)
US Patent
Affinity DataIC50: 189nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Mus musculus (mouse))
Johnson & Johnson Pharmaceutical
Johnson & Johnson Pharmaceutical
Affinity DataIC50: 190nMAssay Description:The enzyme was assayed with a biotinylated peptide substrate and test compounds in the presence of 10 uM ATP/[gamma-33P]ATP in a streptavidin coated...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Homo sapiens (Human))
Shengke Pharmaceuticals (Jiangsu)
US Patent
Shengke Pharmaceuticals (Jiangsu)
US Patent
Affinity DataIC50: 214nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Homo sapiens (Human))
Shengke Pharmaceuticals (Jiangsu)
US Patent
Shengke Pharmaceuticals (Jiangsu)
US Patent
Affinity DataIC50: 293nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Homo sapiens (Human))
Shengke Pharmaceuticals (Jiangsu)
US Patent
Shengke Pharmaceuticals (Jiangsu)
US Patent
Affinity DataIC50: 298nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Homo sapiens (Human))
Shengke Pharmaceuticals (Jiangsu)
US Patent
Shengke Pharmaceuticals (Jiangsu)
US Patent
Affinity DataIC50: 330nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Homo sapiens (Human))
Shengke Pharmaceuticals (Jiangsu)
US Patent
Shengke Pharmaceuticals (Jiangsu)
US Patent
Affinity DataIC50: 344nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Homo sapiens (Human))
Shengke Pharmaceuticals (Jiangsu)
US Patent
Shengke Pharmaceuticals (Jiangsu)
US Patent
Affinity DataIC50: 388nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Homo sapiens (Human))
Shengke Pharmaceuticals (Jiangsu)
US Patent
Shengke Pharmaceuticals (Jiangsu)
US Patent
Affinity DataIC50: 435nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Homo sapiens (Human))
Shengke Pharmaceuticals (Jiangsu)
US Patent
Shengke Pharmaceuticals (Jiangsu)
US Patent
Affinity DataIC50: >500nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
